Investor Presentaiton

Comprehensive Global Partnership Enhances Our Overall Development from R&D to Commercialization Continued solid collaborations with global pharmaceutical and biotech companies Lilly. Roche • Total deal value exceeds US$2.5bn¹ Including upfront payment of US$256m¹ Access to Roche's bispecific antibody and Universal CART technologies Out-license ex-China global rights of up to US$ 2.1bn payments and royalties • • As integrated platform with validated capabilities, Striving to be the best choice for our partners R&D: 1000+ in-house R&D team with top expertise and execution capability in clinical operation, quality control, registration experience to accelerate the R&D progress for our partners CMC: World-class CMC with best quality system validated by long MNC partnerships to support potential production needs of our partners Commercial: 1600+ commercial team with strong presence in oncology proven by TYVYT's leading position in China PD-1 market within 2 years of launch, and rich experienced professional team in non-oncology. THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Making Cancer History Coherus BIOSCIENCES Hanmi Incyte . Licensed in 3 clinical-stage molecules Demonstrated our capability to help global partners bring their innovative therapies into China Note: 1. Including both 2015 and 2020 strategic deals with Eli Lilly, not including royalties Innovent EpimAb Biotherapeutics etana Biotech sirna mics Advancing RNAi Therapeutics Confidential Copyright©2021 Innovent Biologics We Discover New Drugs 微芯生物 CHIPSCREEN SHENOGEN PHARMA GROUP 驯鹿医疗 ALECTOR of Adimab в որ Hutchison Medi Pharma IASO BIOTHERAPEUTICS 11

View entire presentation